Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

• the present invention relates to de novo compositions of matter for the treatment of AIDS.
• the present invention further relates to the de novo compositions of m& er containing TNF inhibitors and antiviral agents selected from the group of reverse transcriptase inhibitors, protease inhibitors, gene inhibitors (of such genes as gag, env, tat, rev, and pol), myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• a drug should give a patient a lasting cure, or at least improve the condition of the patient having a particular disease while causing minimal side effects.
• Latest advances in drug research rely on the systematic research and further understanding of the disease process at the molecular level.
• HIV Human Immunodeficiency virus
• AIDS Acquired Immunodeficiency Syndrome
• the most widely accepted therapeutic composition for treating AIDS is the compound azidothymidine, also known as AZT.
• Recent discoveries relating to AIDS have implicated tumor necrosis factor as a stimulatory agent in the growth of HIV.
• Tumor necrosis factor inhibitors which have been studied in the past include thalidomide, pentoxifylline and xanthine derivatives.
• TNF tumor necrosis factor
• Antiviral therapy such as therapy for Human Immunodeficiency Virus
• Viruses are basically subcellular particles that can live only as intracellular parasites. They basically consist of a genome of RNA or DNA (single or double stranded), packaged inside a protein, and in some cases, with a lipid envelope covering the whole particle. Additionally, these particles infect cells, and replicate within the infected cell using much of the host cell apparatus needed to synthesize macromolecules (e.g., DNA, RNA, protein).
• TNF inhibitor is administered to a patient with other pharmaceutical compounds such as reverse transcriptase inhibitors, gene inhibitors, and HIV protease inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• other pharmaceutical compounds such as reverse transcriptase inhibitors, gene inhibitors, and HIV protease inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• compositions of matter and uses which include tumor necrosis factor inhibitors together with anti- AIDS agents, reverse transcriptase inhibitors, HIV protease inhibitors, gene inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines and in combined formulations therewith.
• a further object of the present invention is a method for the therapeutic treatment of HIV infections by administering concurrently a combination of a tumor necrosis factor inhibitor and one or more compounds selected from the group consisting of reverse transcriptase inhibitors, HIV protease inhibitors, gene inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• the present invention deals with compositions of matter useful for therapeutic treatment of HIV and being a combination of tumor necrosis factor inhibitors and a compound selected from the group consisting of reverse transcriptase inhibitors, HIV protease inhibitors, gene inhibitors, myristoylation inhibitors, cell- virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• the preferred compounds which are used as tumor necrosis factor inhibitors are thalidomide, pentoxifylline, and xanthine derivatives.
• Some of the preferred reverse transcriptase inhibitors include azidothymidine (AZT), dideoxy inosine (ddl), dideoxycytidine (ddC), fluorodideoxythymidine (FddT), as well as other compounds such as D4T, FddT 3TC, BI-RG-587, R-82150 and L697639 whose structures are shown below.
• reverse transcriptase inhibitors include:
• the preferred compounds which would act as gene inhibitors would be benzodiazepine derivatives.
• One promising agent which inhibits the tat gene is RO-24-7429 which is a benzodiazepine shown below.
• the preferred inhibitors of myristoylation would be:
• the preferred inhibitors of cell-virus binding include:
• the preferred inhibitors of LTR promoter sites would include:
• Triplex-forming oligonucleotide • Strand 3B of triplex forming oligonucleotide
• the preferred inhibitors of platelet aggregation would include:
• the preferred ribosome inactivators would include:
• the preferred prophylactic and therapeutic HIV vaccines would be:
• the present invention presents a method of treating HIV by combination therapy which includes administering a tumor necrosis factor inhibitor and, independently, a compound selected from the group of reverse transcriptase inhibitors, HIV protease inhibitors, gene inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• a tumor necrosis factor inhibitor and, independently, a compound selected from the group of reverse transcriptase inhibitors, HIV protease inhibitors, gene inhibitors, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines.
• Example 1 200 milligrams of thalidomide are mixed with 400 milligrams of AZT. The active ingredients are triturated and Q.S. with lactose to selected capsule size.
• thalidomide 200 milligrams of thalidomide are mixed with 500 milligrams of ddl.
• the active ingredients are triturated and Q.S. with lactose to selected capsule size.
• Example 3 300 milligrams of thalidomide are mixed with 500 milligrams of ddC.
• the active ingredients are triturated and Q.S. with lactose to selected capsule size.
• Example 4 200 milligrams of pentoxifylline are mixed with 500 milligrams of AZT. The active ingredients are triturated and Q.S. with lactose to selected capsule size. Example 5.
• pentoxifylline 300 milligrams of pentoxifylline are mixed with 500 milligrams of ddl.
• the active ingredients are triturated and Q.S. with lactose to selected capsule size.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Molecular Biology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22286225

Family Applications (1)

Country Status (3)

Families Citing this family (2)

Family Cites Families (2)

• 1994
  • 1994-08-03 EP EP94922777A patent/EP0712310A1/de not_active Withdrawn
  • 1994-08-03 WO PCT/US1994/008741 patent/WO1995004525A2/en not_active Application Discontinuation
  • 1994-08-03 AU AU73763/94A patent/AU7376394A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events